Immunotherapy success rates for colon cancer depend almost entirely on one biological feature of the tumor: whether it has a characteristic called microsatellite instability-high (MSI-H). For the roughly 15% of colon cancer patients whose tumors test positive for MSI-H, immunotherapy produces strong responses, with tumor shrinkage in 40% to 65% of cases and five-year survival rates above 50% even in advanced disease. For the remaining 85% with microsatellite stable (MSS) tumors, immunotherapy alone has been largely ineffective, with response rates near zero in most trials.
That single biomarker distinction is the most important thing to understand about immunotherapy and colon cancer. The numbers look very different depending on which side of it you fall.
Why MSI-H Status Changes Everything
MSI-H tumors have a defect in their DNA repair machinery. When cells can’t fix copying errors in their DNA, they accumulate far more mutations than normal. Those mutations create abnormal proteins on the surface of cancer cells, which act like flags that the immune system can recognize. Immunotherapy drugs called checkpoint inhibitors work by removing the brakes that cancer puts on immune cells, so more mutations means more targets and a stronger immune attack.
MSS tumors, by contrast, have relatively few mutations and create an environment around the tumor that actively suppresses immune activity. Checkpoint inhibitors given alone produce a response rate of 0% in multiple trials for MSS colon cancer. That’s not a rounding error. Two separate studies testing standard immunotherapy drugs in MSS patients recorded zero objective responses.
About 15% of the roughly 150,000 Americans diagnosed with colorectal cancer each year have MSI-H tumors. Testing for this biomarker is now standard practice at diagnosis, typically done on the biopsy or surgical tissue. If you’ve been diagnosed with colon cancer and haven’t discussed your MSI status with your oncologist, it’s worth asking directly.
Response Rates for MSI-H Colon Cancer
For patients with advanced MSI-H colon cancer, the results vary by which immunotherapy approach is used. A single checkpoint inhibitor produces tumor shrinkage in roughly 31% to 40% of patients. Combining two checkpoint inhibitors that work through different mechanisms pushes response rates significantly higher, to around 55% to 65%.
The CheckMate 142 trial, one of the landmark studies in this space, found a 65% objective response rate with the combination approach compared to 31% with a single agent. A subsequent randomized trial, CheckMate 8HW, confirmed that the combination was superior to both single-agent immunotherapy and standard chemotherapy. Based on these results, current treatment guidelines now give top-tier recommendations to both combination immunotherapy and single-agent immunotherapy as first-line options for advanced MSI-H colorectal cancer.
Long-term survival data from the KEYNOTE-177 trial, which compared immunotherapy to chemotherapy as a first treatment for metastatic MSI-H colorectal cancer, showed five-year overall survival rates of 54.8% for immunotherapy versus 44.2% for chemotherapy. That 10-percentage-point gap is meaningful in stage IV cancer, where historical survival rates with chemotherapy alone were considerably lower. Progression-free survival with the combination approach held at 71% at 12 months, meaning nearly three out of four patients had not seen their cancer worsen after a year.
The Rectal Cancer Result That Made Headlines
One of the most striking findings in cancer research in recent years came from a small trial of immunotherapy for MSI-H rectal cancer. All 12 patients who completed treatment had a clinical complete response, meaning no detectable cancer remained on imaging, biopsy, endoscopy, or physical exam. A 100% complete response rate is virtually unheard of in oncology, even in a small study. These patients avoided both surgery and radiation, which for rectal cancer can carry life-altering side effects.
The trial was small enough that the confidence interval ranged from 74% to 100%, so larger studies will refine the true number. But the result fundamentally changed how oncologists think about treating MSI-H rectal tumors, opening the door to an organ-sparing approach where immunotherapy replaces the traditional sequence of radiation, chemotherapy, and surgery.
Immunotherapy Before Surgery
Giving immunotherapy before surgery (called neoadjuvant treatment) for MSI-H colon cancer has shown remarkably high pathological response rates, meaning that when surgeons remove the tumor after treatment, pathologists find most or all of the cancer cells have been destroyed. Across several studies, major pathological response rates ranged from 57% to 98%, and complete pathological response, where no living cancer cells remain in the surgical specimen, occurred in about 68% of patients.
These numbers suggest that for many MSI-H patients with earlier-stage disease, immunotherapy given before surgery can dramatically reduce or eliminate the tumor, potentially allowing less extensive operations or raising the question of whether some patients might avoid surgery altogether, as seen in the rectal cancer trial.
The Challenge for MSS Colon Cancer
For the 85% of colon cancer patients with MSS tumors, immunotherapy remains a difficult problem. Standard checkpoint inhibitors used alone or in pairs have consistently failed to produce meaningful responses, with rates below 10% in nearly every study and at 0% in several.
The biological reasons are clear. MSS tumors carry far fewer mutations, giving the immune system fewer targets. The tissue surrounding these tumors is also more immunosuppressive, meaning immune cells that do arrive get shut down before they can attack. Liver metastases, which are the most common site where colon cancer spreads, appear to create an additional barrier to immune response. Multiple trials have found that patients with liver metastases respond even more poorly to immunotherapy than other MSS patients.
One combination under investigation has shown early promise: a newer pair of checkpoint-targeting drugs produced a 22% response rate in MSS patients without liver metastases, though those with active liver spread still showed a 0% response. This is the first approach to break the 10% barrier for MSS disease, but it remains experimental and is not yet part of standard treatment.
Side Effects to Expect
Immunotherapy side effects differ from chemotherapy. Rather than hair loss or severe nausea, the main risks come from the immune system attacking healthy tissue. For colon cancer patients specifically, the most studied risk is immunotherapy-induced colitis, an inflammation of the colon that can cause diarrhea, abdominal pain, and in severe cases, bowel perforation.
Severe colitis occurs in about 2.5% of patients overall. The rate is slightly higher in patients receiving immunotherapy as their first treatment (3.4%) compared to those who’ve had prior therapies (1.8%). Combination immunotherapy and single-agent approaches carry similar rates of severe colitis, around 2.1% to 2.5%. Most cases are manageable, but they require prompt communication with your treatment team if symptoms develop.
Other immune-related side effects can affect the skin, liver, thyroid, and lungs, though these are less specific to colon cancer patients and occur across all tumor types treated with checkpoint inhibitors. Most are mild to moderate and reversible with treatment interruption or short courses of immune-suppressing medication.
What Determines Your Eligibility
The single most important step is getting your tumor tested for MSI or mismatch repair status. This testing is done on tumor tissue, either from a biopsy or surgery, using one of two methods: a protein-based test that looks at the repair machinery directly, or a DNA-based test that measures instability in the genetic sequence. Both are widely available and are recommended for all colorectal cancer patients regardless of stage or age.
If your tumor is MSI-H, immunotherapy is now a first-line option for metastatic disease, with the combination approach receiving the strongest recommendation in current guidelines. For earlier-stage MSI-H disease, neoadjuvant immunotherapy is increasingly being studied and used. If your tumor is MSS, immunotherapy outside a clinical trial is generally not recommended, though the landscape for MSS patients is evolving as new combination strategies are tested.